While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > BUSINESS
BUSINESS
- Taisho Files Autoinjector Version of RA Med Nanozora in Japan
September 29, 2022
- Maruishi/Kissei’s Pruritus Med Difelikefalin Filed in Japan
September 29, 2022
- Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
- Evusheld Can Fulfill Immunodeficient Patients’ Needs: AstraZeneca Japan VP
September 28, 2022
- Sumitomo Appeals to US Court to Overturn Dismissal of Latuda’s Use Patent
September 28, 2022
- Janssen’s CAR-T Therapy Carvykti Approved in Japan
September 27, 2022
- Promotions via In-Hospital Seminars, Webinars, Internet Channels Log Two-Digit Growth in August: Intage
September 27, 2022
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- Hospira Barred from Launching Lexiscan Generic until Oct. 5: Astellas
September 27, 2022
- Healios Licenses Non-Exclusive Rights for iPSC Line to RxCell
September 26, 2022
- Towa Prevails in IP High Court Ruling for Livalo Damage Suit, Kowa Mulls Next Step
September 22, 2022
- Pfizer Japan to Discontinue Ibrance’s Capsule Products
September 22, 2022
- Janssen Aims to Rank Among Top 3 Drug Makers in Japan by 2024: Local Chief
September 22, 2022
- UCB’s Epilepsy Drug Brivaracetam Hits PIII Goal, Japan Submission Eyed in 2023
September 21, 2022
- Otsuka’s Lupus Nephritis Med Lupkynis Wins European Greenlight
September 21, 2022
- Takeda’s CMV Drug Maribavir Snags EU Panel Backing
September 21, 2022
- Boehringer Ingelheim Revamping Biz Sites in Japan to Spur Communications among Drug Reps
September 20, 2022
- Daiichi Sankyo Apologizes for Arrest of Employee
September 20, 2022
- Shionogi Eyes EUA of COVID Pill in South Korea via Sublicense to Local Firm
September 20, 2022
- Daiichi Sankyo Employee Nabbed for Killing Wife with Methanol
September 20, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…